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Clinical epidemiological studies investigate whether an
exposure, or risk factor, is causally related to the
development or progression of a disease or mortality. It
might be of interest to study whether this relation is different
in different types of patients. To address such research
questions, the presence of interaction among risk factors can
be examined. Causal interaction between two risk factors is
considered most clinically relevant in epidemiology. Causal
interaction occurs when two risk factors act together in
causing disease and is explicitly defined as a deviation from
additivity on a risk difference scale. Statistical interaction can
be evaluated on both an additive (absolute risk) and
multiplicative (relative risk) scale, depending on the model
that is used. When using logistic regression models, which
are multiplicative models, several measures of additive
interaction are presented to evaluate whether the magnitude
of an association differs across subgroups: the relative excess
risk due to interaction (RERI), the attributable proportion due
to interaction (AP), or the synergy index (S). For a transparent
presentation of interaction effects the recent Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) Statement advises reporting the separate effect of
each exposure as well as the joint effect compared with the
unexposed group as a joint reference category to permit
evaluation of both additive and multiplicative interaction.
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INTERACTION BETWEEN EXPOSURES
Clinical epidemiological studies investigate whether an
exposure, or risk factor, is causally related to the development
or progression of a disease or mortality. It might be of
interest to study whether this relation is different in different
types of patients. In other words, it might be of interest to
study whether the effect of one risk factor on a certain
outcome is dependent on the presence of another risk factor.
For example, we might want to know whether the observed
relation between exposure to lifestyle risk factors and the
development of chronic kidney disease differs between men
and women.1 Besides observational studies, randomized
clinical trials commonly evaluate whether treatment effects
differ across certain subgroups. For example, the Modifica-
tion of Diet in Renal Disease Study in 585 patients with
nondiabetic kidney disease studied whether effect of a low
protein diet intervention on kidney failure and all-cause
mortality differed between subgroups of blood pressure
assignment, baseline GFR, baseline level of proteinuria, cause
of kidney disease, age and sex.2 To address such research
questions, the presence of interaction is examined.
In literature, many terms are being used to indicate
interaction, for example joint effect or combined effect,
synergy, interdependence, heterogeneity of effects, non-
uniformity of effects, effect modification, or plain subgroup
analyses. In principle, they all mean the same thing: whether
the effect of one risk factor is modified by the value of
another risk factor. However, there are two different concepts
of interaction that may be distinguished: the theoretical
concept of causal interaction and the concept of statistical
interaction.3,4
The purpose of this paper is to explain how interaction
can be evaluated and reported in applied data analysis, and to
illustrate to what extent different approaches can result in
different answers to a research question.
CAUSAL INTERACTION
Causal interaction is a theoretical concept of causation and is
explicitly defined as a deviation from additivity of the
absolute effects (risk differences) of the two risk factors under
study,3,5–7 meaning that the combined effect of two exposures
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is more or less than the sum of their separate effects. Causal
interaction between two risk factors thus occurs when they
act together in causing disease, or whenever the effect of one
is dependent on the presence of the other.6 In fact, most
causes of disease are dependent on the presence of other risk
factors to result in a certain disease. The concept of causal
interaction thereby refers to a situation that happens all the
time in biology.3 Sometimes, the term biological interaction
has been used when interaction is evaluated on an additive
scale. However, it must be noted that an observed interaction
effect may have no implications about underlying biological
mechanisms. Therefore, instead of the term ‘biological
interaction’ the term ‘causal interaction’ may be preferred
to indicate additive interaction between two risk factors.8
The additive scale is commonly used in clinical epide-
miology, when numbers of events (for example deaths) are
counted and every additional observed event (death) in
subjects exposed to two risk factors is intuitively considered
as excess, implying interaction. By using absolute risks,
additive interaction is considered most clinically relevant
because of its potential implications for public health. In
example 1 we will first examine the presence of causal
interaction.
Example 1: interaction between chronic kidney disease and
cardiovascular disease
A study explored the interaction between chronic kidney
disease (CKD) and cardiovascular disease (CVD) in the
association with a composite outcome of cardiac events,
stroke and death in 10 years of follow-up of 26,147
individuals from four community-based studies.9 The
authors hypothesized that as CKD is a risk factor of CVD
whereas CVD may promote CKD, CKD and CVD might have
a synergistic effect on future cardiovascular and mortality
outcomes. Table 1 shows the rates of the composite outcome
per 1000 person-years (py).
What can be concluded from Table 1? In persons without
CKD and CVD at baseline the rate of the composite outcome
was 16.9/1000 py. This can be considered as the background
rate of all persons without CVD and CKD at baseline, 16.9
per 1000 py got a cardiac event, or died within 10 years. In
persons with CKD at baseline this was 44.9/1000 py, resulting
in a risk difference of 44.916.9¼ 28/1000 py. This addi-
tional 28/1000 py can be considered as purely due to exposure
to CKD. In persons with CVD at baseline the rate was
52.7/1000 py, 52.716.9¼ 35.8/1000 py more due to expo-
sure to CVD. When no interaction between CKD and CVD
would be present, we would expect an outcome rate in
persons exposed to both CKD and CVD at baseline of
16.9þ 28þ 35.8¼ 80.7/1000 py: 16.9/1000 py will get the
outcome anyway, an extra 28/1000 py due to exposure to
CKD and an additional 35.8/1000 py due to exposure to
CVD. The observed rate, however, was 116.4/1000 py.9 Thus,
the composite outcome occurred in 116.480.7¼ 35.7
persons per 1000 py more than we would expect on the
basis of the sum of the separate effects of CVD and CKD,
implying the presence of causal interaction between CKD and
CVD. In other words, due to interaction between CKD and
CVD, an excess risk of 35.7/1000 py has been observed.
Although some consider every single extra case a departure
from additivity, the clinical relevance of the magnitude of the
effect needs of course to be evaluated on the basis of
knowledge on the subject matter. Note that in this first
example, we evaluated the presence of interaction on the
basis of risk differences on an additive scale (the calculation
of risk differences was reported in an earlier paper of this
series10).
STATISTICAL INTERACTION
Statistical interaction refers to the inclusion of a product
term of the two risk factors under study in a statistical model,
which is explained below. In many studies, the presence of
interaction between two risk factors is assessed by testing
whether the regression coefficient of such a product term is
statistically significant, representing the excess risk due to
interaction of the exposures. However, in this way, the
presence of interaction is tested on the underlying scale of the
model. A previous paper in this series explained the
applications of linear and logistic models.11 The following
equations show that the underlying scales of these models are
different.
The regression equation of the linear regression model
including a product term, or interaction term, is
EðyÞ ¼ b0þb1X1þb2X2þb3X1X2
Where E(y) is the estimated effect, b0 is the intercept that can
be interpreted as the background risk, b1 and b2 are the
regression coefficients of the risk factors X1 and X2. By
including the product term (X1X2) the interaction effect is
estimated through estimation of the regression coefficient b3.
When for example E(y) represents the mean glomerular
filtration rate (GFR), X1 indicates whether the patient
received a certain diet (X1¼ 1) or not (X1¼ 0), and X2
indicates whether patients are men (X2¼ 1) or women
(X2¼ 0), solving the regression equation in women without
the diet would result in GFR¼ b0, in women with the diet
GFR¼ b0þ b1, in men without the diet GFR¼ b0þ b2, and
in men with the diet GFR¼ b0þ b1þ b2þ b3. A statistically
significant interaction effect (when the regression coefficient
b3 tests significant) would mean in this example that the
effect on GFR is (b3) different in men than in women.
Table 1 | Rates of composite outcome per 1000 person-years
in 26,147 individuals during 10 years of follow-up without
CKD or CVD, with CKD or CVD or with both CKD and CVD at
baseline9
CKD CKD+
CVD 16.9 44.9
CVD+ 52.7 116.4
CKD; Chronic kidney disease, CVD; Cardiovascular disease, ; without exposure,
+; with exposure.
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As linear regression models are additive models (the effects
sum up), the absence of an interaction term in such a model
(b3¼ 0) implies exact additivity of effects (GFR¼
b0þ b1þ b2). A statistically significant regression coefficient
of the product term (b3) indicates a deviation of additivity,
implying the presence of interaction on an additive scale.
In contrast, logistic models, including the Cox regression
model, are multiplicative models (the effects multiply). The
regression equation of the logistic regression model including
an interaction term is
ln½ p=ð1  pÞ ¼ b0þb1X1þb2X2þb3X1X2
This equation can be rewritten as
½ p=ð1  pÞ ¼ eb0þb1X1þb2X2þb3X1X2 ¼ eb0eb1X1eb2X2eb3X1X2
where p is the proportion of individuals with the outcome
and ½ p=1  p is the odds of the outcome. The absence of a
product term in such a model (b3¼ 0) implies a multi-
plicative relation between the effects ðeb0eb1X1eb2X2Þ,
whereas a statistically significant product term between two
risk factors implies departure from multiplicativity, rather
than from additivity.
Thus, by including a product term in the model, it
depends on the model that is used (linear or logistic) whether
the interaction effect is tested on an additive (risk difference)
or a multiplicative (relative risk) scale. The study of example
1 illustrates how difficult it is to interpret interaction terms in
modeling: the variables CKD, CVD and the product term of
CKD and CVD were also included in a multivariate Cox
regression model. The regression coefficient of the interaction
term was not significant and it was concluded that the inter-
relationship between CKD and prior CVD was only additive,9
whereas a departure from multiplicativity had been tested.
It must be noted that many studies lack sufficient power to
detect interaction effects statistically significant in subgroup
analyses. As a result, a P-value higher than 0.05 may not
always mean the absence of statistical interaction. Further-
more, any absence of departure from multiplicativity does
not preclude departure from additivity. Even when relative
risks are similar within two subgroups of a risk factor,
interaction may be present on an additive scale, especially in
case of a strong risk factor like age. The modification of diet
in renal disease study for example did not detect an
interaction effect on a multiplicative scale between age and
diet (P¼ 0.73 for kidney failure or death) in 585 patients
with nondiabetic kidney disease.2 However, because the
mortality rate among older patients is much higher than
among younger patients, similar hazard ratios may result in a
large risk difference, suggesting the presence of interaction on
an additive scale.
With the crude data of Table 1, the presence of interaction
can also be evaluated on a multiplicative, or relative scale. In
persons with CKD at baseline the rate of the composite
outcome is 2.66 times greater than the background rate
(16.9 2.66¼ 44.9 per 1000 py). In persons with CVD at
baseline, the rate is 3.12 times greater than the background
rate (16.9 3.12¼ 52.7 per 1000 py). On a multiplicative
scale the expected rate in the group with both CKD and CVD
would be 16.9 2.66 3.12¼ 140.3 per 1000 py (or, 8.28
times greater than the background rate). As the observed rate
was 116.4/1000 py (only 6.89 times greater than the back-
ground rate), the interaction effect is less than multiplicative.
This is also considered as a departure from multiplicativity.
However, when the same data were evaluated on a risk
difference scale, an excess risk of 35.7/1000 py was detected in
patients with both CKD and CVD. The results are depicted
on both scales in Figure 1 to illustrate that there is interaction
on both an additive and a multiplicative scale. On the basis of
the multiplicative scale the combination of CKD and CVD
appears protective. However, the multiplicative scale may be
obscuring the results as more patients reached the composite
outcome than was expected on the basis of the separated risks
of CKD and CVD, which may be a clinically relevant finding.
Assuming additivity, we will not conclude that there is a
protective effect, but that there is an interaction effect of
CKD and CVD, resulting in excess cases with the composite
outcome.
MEASURES OF ADDITIVE INTERACTION DERIVED FROM
MULTIPLICATIVE MODELS
Hence, when a product term is needed in a logistic model,
interaction is present on a multiplicative scale. As logistic
regression is at this moment the most commonly used model
in clinical research, most analyses are performed on a
multiplicative scale. Although counterintuitive, several mea-
sures have been developed to evaluate interaction on an
additive scale, using relative measures of effect derived from
statistically multiplicative models.6 These measures have been
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Figure 1 | Unadjusted rates of composite outcome per 1000
person-years (left y axis) and on a relative risk scale (right y
axis) in 26,147 individuals during 10 years of follow-up
without CKD or CVD, with CKD or CVD, or with both CKD and
CVD at baseline. The dotted line indicates the background risk
(16.9/1000 person-years; RR¼ 1); the straight line indicates exact
additivity of effects; the dashed line indicates exact
multiplicativity of effects. As the observed rate of the composite
outcome is 116.4/1000 py, there is both a departure from
additivity and a less than multiplicative effect. CKD¼Chronic
kidney disease, CVD¼Cardiovascular disease.
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developed originally for use in case–control studies, in which
the OR is the measure of effect because incidence rates and
risk differences cannot be estimated.10
For the calculations of these measures of additive
interaction between two risk factors a new composite variable
with four categories must be computed, indicating a category
of joint exposure to both risk factors (þ þ ), a category of
exposure to one of the risk factors only (þ or þ ), and
the joint reference category of no exposure (background risk,
  or 1). Logistic regression analysis is then used to
estimate the ORs using this new indicator variable. The ORs
in the formulas below can be replaced by hazard ratios (HR)
when using Cox regression models. Three different measures
exist to quantify the amount of interaction on an additive
scale:6
(1) The relative excess risk due to interaction (RERI),
which can be interpreted as the risk that is additional to the
risk that is expected on the basis of the addition of the ORs
under exposure, calculated as the difference between the
expected risk and the observed risk:
RERI ¼ ORþþ  ORþ  ORþ þ 1
(2) The attributable proportion due to interaction (AP),
which is interpreted as the proportion of disease or mortality
that is due to interaction among persons with both
exposures: AP¼RERI/ORþ þ .
(3) The synergy index (S), which can be interpreted as the
excess risk from exposure to both exposures when there is
interaction relative to the risk from exposure without
interaction: S¼ [ORþ þ1]/[(ORþ1)þ (ORþ1)].
In the absence of an interaction effect, RERI and AP equal
0 and S equals 1.
For the purpose of the example, we provide the
calculations of these measures of additive interaction with
the crude relative risks provided in Figure 1:
The RERI would be 6.892.663.12þ 1¼ 1.11, the AP
1.11/6.89¼ 0.16, and the synergy index 5.89/
(1.66þ 2.12)¼ 1.56. When examining the presence of
additive interaction with adjusted hazard ratios or odds
ratios, the synergy index should be the measure of choice
(indicated below). Although some consider every departure
from 0 (RERI and AP) or 1 (S) as evidence for the presence of
interaction, there are several possibilities to calculate
confidence intervals around these measures of interac-
tion.12–15 Although we focus here on dichotomous risk
factors (for example, the presence or absence of CKD), a
recent paper provided the methods to estimate the interac-
tion on an additive scale between continuous risk factors (for
example, age in years) in a logistic regression model.14
In practice, the estimation of these measures is straight-
forward. However, several considerations need to be taken
into account when using these measures in the examination
of interaction on an additive scale. First, the RERI, AP and S
depend on the chosen reference category. In general, this
should be the unexposed group as joint reference category
(for example, the group without CKD and CVD at baseline).
For some variables it may not always be obvious which
category to choose as joint reference (for example, men or
women, young or old?). Because the measures are difficult to
interpret when effects are protective (when the OR of one of
the risk factors is below 1) they are best calculated with non-
protective effects; the lowest risk should be chosen as the
joint reference category, resulting in a positive risk differ-
ence.6 Second, RERI and AP are not straightforward to
interpret after including covariates in the models to control
for confounding.16,17 The problem is that RERI and AP vary
across strata defined by covariates, whereas the fundamental
interaction parameter is unvarying. For example, after
adjustment for sex in example 1, the RERI for interaction
between CKD and CVD may differ when calculated
separately for men and women. In contrast, the synergy
index does not vary across strata, which suggests that it is the
measure of choice in multivariate models.16 Third, similar to
the OR, one should realize that the RERI, AP and S based on
logistic regression only approximate the true measures in
closed cohorts.16,18,19 Finally, certain data may better fit
additive or multiplicative models statistically. It may seem
counterintuitive when variables are modelled on a multi-
plicative scale that two risk factors are selected to be
examined on an additive scale. However, for a causal
interpretation, the presence of interaction needs to be
examined on an additive (risk difference) scale.3,6
RECOMMENDATION FOR REPORTING OF INTERACTION
To prevent confusion and ambiguous conclusions the
presentation of the methods and results must clarify which
method and scale the authors have used to evaluate the
presence of interaction in their research.4 Papers that include
subgroup analyses commonly report P-values of included
product terms in logistic regression models and stratified
results (per subgroup) when P-values are significant. This
reporting is insufficient for the reader to evaluate whether
there is departure from additivity when one wants to
communicate a causal interaction effect.
Example 2: interaction between age and treatment
The Dialysis Clinical Outcomes Revisited trial is a random-
ized trial of sevelamer compared to calcium-based phosphate
binders in 1068 prevalent hemodialysis patients.20 A
significant interaction effect between age and treatment
(P¼ 0.02) was detected in relation to all-cause mortality and
hazard ratios were reported separately for younger patients
(o65 years) (HR:1.18, 95% CI: 0.91–1.53) and older patients
(X65 years) (HR:0.77, 95% CI: 0.61–0.96).
With these results only, the presence of interaction cannot
be interpreted on an additive scale. Because the mortality
rates of each exposure group were also reported we are,
however, able to interpret the interaction effect on an additive
level. The mortality rate in younger patients on calcium-
containing binders was 10.6 per 100 patient-year, 12.5/100 py
in younger patients on sevelamer, and 23.4/100 py in older
patients on calcium-containing binders.20 On the basis of the
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effect of sevelamer in younger patients we would expect a
mortality rate of 25.3/100 py in older patients on sevelamer.
However, the observed mortality rate was 18.3/100 py,
representing an interaction effect of seven deaths per 100
patient-year less than expected on the basis of the separate
effects of older age and sevelamer.
The recent Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) Statement advices a
transparent presentation of the separate effect of each
exposure as well as the joint effect, each relative to the
unexposed group as (joint) reference.21 Such a variable with
the four possible exposure categories will give the reader
sufficient information to evaluate both additive and multi-
plicative interaction.21 The results in the following example
permit evaluation of different scales of interaction.
Example 3. Interaction between renal dysfunction and
impaired fasting glucose
This study in 9918 participants in an antihypertensive
treatment program examined the presence of interaction of
moderate renal dysfunction (MRD) and impaired fasting
glucose (IFG) upon the risk of ischemic heart disease (IHD)
mortality.22 The authors reported that the interaction
product term of MRD and IFG significantly improved
(P¼ 0.001) a Cox regression model. As the regression
coefficient of the product term was not given, the magnitude
and the direction of the interaction effect cannot be
concluded from this information only. However, the authors
furthermore report absolute mortality rates for persons with
normal and impaired fasting glucose within each group of
renal dysfunction, and the hazard ratios from a Cox model
for those with IFG only (HR, 95% CI: 1.48, 1.10–2.00), MRD
only (1.69, 1.16–2.46), and both IFG and MRD (0.71,
0.36–1.43), with the reference being neither IFG or MRD.22
These HRs can be used to calculate for example the RERI
(RERI¼ 0.71–1.691.48þ 1¼1.46; indicating that because
of interaction between IFG and MRD, the hazard ratio was
1.46 lower than expected from the addition of the separate
effects of IFG and MRD). The authors herewith provide the
reader with sufficient information to evaluate the presence of
interaction on both an additive and multiplicative scale. In
contrast to prior expectations, renal dysfunction seemed to
protect hypertensive patients with impaired fasting glucose
from mortality due to IHD. The authors are cautious in the
interpretation of this effect as their finding was unanticipated
and warrant further study.22
CONCLUSION
To conclude, many terms to indicate interaction exist. For a
causal interpretation interaction is measured on an additive
scale. When using product terms in statistical models one
should consider whether the underlying scale of the model is
additive, or multiplicative. When using logistic regression
models, measures of additive interaction can be used to
evaluate whether the magnitude of an association differs
across subgroups. For a transparent presentation of interac-
tion effects the recent STROBE Statement advices to report
the separate effect of each exposure as well as the joint effect
compared to the joint reference category to permit evaluation
of both additive and multiplicative interaction.
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